We are live on ! Find out more

SDEV

Stablecoin Development Corp

SDEV

Market cap $56.7M

1.12 USD

-0.02

1.75%

At close Updated Aug 24, 4:00 PM EDT

Pre-market

After hours

1.05

-0.07

6.25%

1 day

-1.75%

5 days

14.29%

1 month

1.82%

3 months

-14.5%

6 months

-32.12%

Year to date

-96.18%

1 year

-75.28%

5 years

-99.97%

10 years

-99.99%

About: Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.

Employees: 4

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

Abbott Cooper PLLC is investigating fiduciary duty claims for SDEV (formerly NovaBay Pharmaceuticals) holders who owned shares before August 19, 2025.

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders

Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results

Staking revenue of $2.2 million for the quarter and $4.7 million for the first half of 2026 SDEV grew its SKY position to 2.29 billion tokens (approximately 10% of total SKY supply) and eliminated all remaining warrant liabilities from its balance sheet WEST PALM BEACH, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- Stablecoin Development Corporation (NYSE American: SDEV) (the “Company” or “SDEV”), an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems and providing public market access to the stablecoin economy, yesterday reported financial results for the second quarter and first half ended June 30, 2026.

Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly NovaBay Pharmaceuticals, Inc.) Stockholders

STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Stablecoin Development Corporation (Nasdaq: SDEV) (formerly NovaBay Pharmaceuticals, Inc.) who held their shares prior to August 19, 2025.

SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly NovaBay Pharmaceuticals, Inc.) Stockholders

Stablecoin Development Corporation Reports First Quarter 2026 Financial Results

Company Generated $22.3 Million of Operating Income and Reported $552.4 Million of GAAP Net Income, Including Significant Non-Cash Warrant-Related Gains

Stablecoin Development Corporation Reports First Quarter 2026 Financial Results

NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19%

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) announced Monday its corporate name change to Stablecoin Development Corporation, signaling a full shift toward a cryptocurrency-focused strategy.

NovaBay Rebrands To Stablecoin Development Corp In Full Crypto Pivot— Pharma Company's Stock Climbs 19%

NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update

Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion SKY tokens

NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update

NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's continued listing standards.

NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards

NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) previously announced a one-time special cash dividend of $0.80 per share for the Company's common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025.

NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting

NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025.

NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Investment to support NovaBay's continued public listing and provide funding for a future strategic transaction Investment to support NovaBay's continued public listing and provide funding for a future strategic transaction

NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

See News Rankings

Price charts implemented using Lightweight Charts™